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The aim of the current study was to analyse the augmentation of minocycline with bupropion in treating depression. ‘Saline’ (10 ml/kg), 
‘minocycline per se’ (25 mg/kg), ‘minocycline per se’ (50 mg/kg), ‘bupropion per se’ (5 mg/kg), ‘bupropion per se’ (10 mg/kg) and ‘bupropion 
+ minocycline’ (5 mg/kg + 25 mg/kg each) were administered to mice via the intraperitoneal route. In the forced swim and tail suspension 
test, the immobility period was analysed after 30 min of the treatment. Monoamines like dopamine, norepinephrine and serotonin levels 
were analysed in brain areas such as the whole brain, hippocampus and cerebral cortex using an HPLC‑fluorescence detector. Euthanasia 
of mice was performed 1 h after treatment. Comparison between the control group and combination therapy and other standard drug 
groups showed a significant decrease in immobility in both antidepressant animal models. The combination of bupropion and minocycline 
showed greater benefits with respect to a  reduction in the immobility time period and enhancement of dopamine, serotonin, and 
norepinephrine levels in the cerebral cortex, hippocampus and the whole brain when compared to the monotherapy treated groups. 
Hence, the side effects may be reduced drastically through this combination by a reduction in the bupropion/minocycline dosage. 
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INTRODUCTION
Depression is often considered as a common mental 
disorder of the brain encompassing feelings of sadness, 
guilt, loss of appetite, tiredness, lack of concentration, 
lack of self‑esteem, lack of interest or pleasure, and dis‑
turbed sleep. Depression is common worldwide, with an 
estimated 300 million people affected. Depression adds 
to the global burden of disease (according to the World 
Health Organization). The antidepressants available are 
associated with adverse effects and a slow onset of action, 
which basically restricts their effectiveness, and hence 
the prerequisites of the therapy of depression are still un‑
met (Mojtabai, 2009; Richelson, 2013). Augmentation ther‑
apy as a second‑line treatment is preferred over first‑line 
monotherapy because the latter is associated with a lower 
success rate (60‑70%) (Thase et al., 2007). The therapeu‑
tic potential of the new generation drugs like venlafax‑
ine (a dual reuptake inhibitor), reboxetine (a selective 
NE‑reuptake inhibitor) or multiple receptor‑acting drugs 
like bupropion, mirtazapine, trazodone and nefazodone 
may be positively influenced by decreased adverse reac‑
tions due to decreased affinities for other systems (Bondy, 
2002). Studies have demonstrated that bupropion increas‑
es monoaminergic neurotransmission in a different man‑
ner compared to several other antidepressants. In rat and 
mouse studies, presynaptic (by affecting serotonin release 
or reuptake) and postsynaptic (by binding to serotonin 
receptors) alteration of serotonergic neurotransmission 
did not take place via bupropion and its metabolites such 
as threohydrobupropion, erythrohydrobupropion and 
hydroxybupropion, but it did reduce the reuptake of do‑
pamine and norepinephrine into rat and mouse synapto‑
somes (sacs formed by presynaptic neuronal membranes 
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that mimic presynaptic neuronal terminal activity) (Fer‑
ris and Cooper, 1993). It acts through a negative feedback 
mechanism mediated by an autoreceptor (Ascher et al., 
1995). Norepinephrine and dopamine reuptake is inhib‑
ited by bupropion. Due to its dual action, it is considered 
a drug of interest in the treatment of depression (Stahl 
et al., 2004). Bupropion showed antidepressant effects at 
10 mg/kg in mice (Kale and Addepalli, 2014).
Minocycline showed anti‑depressant activity in dif‑
ferent preclinical and preliminary clinical studies. Mi‑
nocycline is known for its neuroprotective properties by 
directly promoting neurogenesis, being a broad spectrum 
tetracycline antibiotic (Soczynska et al., 2012). It also mod‑
ulates immune processes, decreases oxidative stress, and 
increases neuron growth. A double‑blind, randomised, 
placebo‑controlled trial showed benefits of minocycline as 
an adjunct treatment option to reduce the dose of known 
antidepressants and thereby related side effects (Dean et 
al., 2017). A recent review made an overall observation of 
significant benefits in reducing the immobility time peri‑
od and in anhedonia‑based parameters with minocycline 
treatment. The report also suggested the need for consid‑
ering the assessment of antidepressant activity of mino‑
cycline in additional clinical trials (Reis et al., 2019). Mi‑
nocycline is known to reduce the immobility time period 
in mice at 50 mg/kg (Henry et al., 2008; Zheng et al., 2015). 
The evidence suggests the importance of considering mi‑
nocycline and bupropion combinations in the treatment 
of depression. Therefore, the present study considered an 
analysis of minocycline and bupropion combination treat‑
ment in different antidepressant animal models.
METHODS
Animals
Male Swiss Albino mice, weighing in the range of 
20‑30 g, procured from Bombay Veterinary, Mumbai, were 
housed within the animal facility. The animals were housed 
in polycarbonate cages at room temperature (25±2 ⁰C) and 
humidity (50~60%) with a 12:12 hour light/dark cycle. The 
animals were acclimatised for a week before starting ex‑
perimental work where they were given free access to stan‑
dard food and water. A separate set of animals were used 
for the forced swim test (36 animals) and tail suspension 
test followed by brain monoamine estimation (36 animals). 
In total 72 animals were considered for three experiments 
i.e. forced swim test ‑ 36 animals, and the remaining 36 for 
the tail suspension test followed by brain monoamine esti‑
mation). Each group present had 6 animals in the set. Prior 
approval from the Institutional Animal Ethical Committee 
(IAEC) (Approval no: CPCSEA/IAEC/SPTM/P‑02/2016) was 
granted before conducting the studies.
Drug solutions and treatment
Administration of drugs was through the intraperi‑
toneal route. Drug solutions were prepared using saline 
(0.9% w/v of NaCl) as a vehicle. Each animal received 
treatment 30 min prior to treatment with drugs. Animals 
were categorised into six groups. Saline (10 ml/kg) was 
given to the control group. Bupropion (10 mg/kg), mino‑
cycline (50 mg/kg), bupropion (5 mg/kg), minocycline 
(25 mg/kg) and a combination of bupropion (5 mg/kg) 
and minocycline (25 mg/kg) treatment were given to 
groups II, III, IV, V and VI, respectively.
Antidepressant models
Forced swim test (FST)
The forced swim test or behavioural despair test was 
conducted as reported by (Porsolt et al., 1978). On the 
first day, the mice underwent a “pre‑test‑session” for ap‑
proximately 15 min. Each mouse was forced to swim for 
about 15 min in a plexiglass cylinder (12 cm internal di‑
ameter; 21 cm height) which contained water up to 10 cm 
from the bottom at 24±1°C. On the second day, each ani‑
mal was treated 30 min prior to the test session and the 
swimming period was recorded for 6 min. For evaluation, 
the last 5 min session from the total 6 min of the record‑
ed video was utilised. Mice were regarded as immobile 
when no limb movements were observed during floating 
or when only small or slight limb movements necessary 
for floating were seen. The immobility time was calculat‑
ed as seconds denoted by mean ± SEM.
Tail suspension test (TST)
A set of aluminium stands measuring 58 cm (high) 
× 30 cm (wide) were used as apparatus during the TST 
study. At 58 cm height on a horizontally fixed aluminium 
rod, adhesive tape was utilised to suspend each mouse 
by its tail. The tape was placed approximately 1 cm from 
the tip of the tail (Vogel, 2008). Mice received treatment 
30 min before undergoing the 5 min test session. Record‑
ed video of each animal was evaluated for its immobility 
in seconds and denoted as mean ± SEM.
Estimation of monoamines in the brain 
by the HPLC with fluorescence detector  
(HPLC‑FD) method
Monoamine level analysis in the brain was car‑
ried out in 3 areas i.e. the hippocampus, cerebral cor‑
tex, and the whole brain (whole brain=hippocampus 
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+ cerebral cortex + remaining brain tissue). It was con‑
ducted using the HPLC (Shimadzu, LC‑2010C HT) with 
FD (RF‑20A‑prominence, Shimadzu) method (Lakshma‑
na and Raju, 1997; Choudhary et al., 2013; Kale et al., 
2014). Approximately 1 h before euthanasia, mice were 
treated. After performing the TST at a 30 min interval, 
mice heads were dropped in 0.1 M perchloric acid at the 
60 min interval. Perchloric acid was maintained in an 
ice‑cold environment. Weighing of the brain was done 
immediately after removal. The hippocampus, cerebral 
cortex, and the remaining part of the brain were care‑
fully separated, and each part was weighed individually 
and then homogenisation was carried out in 2 ml of 0.1 M 
perchloric acid. This was maintained in an ice‑cold envi‑
ronment. Later, centrifugation of the resulting mixture 
at around 8000 rpm (Eppendorf 5810 R, Rotor F‑45‑30‑11) 
was carried out for 20 min at 4°C. The resulting superna‑
tant was filtered through a 0.45 μm membrane and then 
eventually stored at ‑80°C until further analysis. Injec‑
tion of the samples at room temperature was carried out 
carefully and on a reversed‑phase analytical column, the 
chromatographic separation was observed (Waters, C18, 
5 μm, 25 mm × 0.46 mm). Processing of the gathered data 
was done using LC Solution software. Preparation of the 
mobile phase was carried out using 0.1 M Phosphate buf‑
fer at pH 3.92, which was further adjusted with phos‑
phoric acid, and eventually filtered through a 0.45 μm 
membrane filter. Mobile phase flow rate was adjusted 
to 0.8 ml/min. At an excitation wavelength of 280 nm 
and an emission wavelength of 315 nm, serotonin, do‑
pamine and norepinephrine were spotted. By compar‑
ing the retention time of the sample and the standard 
the monoamine peaks were recognised. According to 
the area under the curve and by means of the respec‑
tive straight‑line equation, the concentration of each 
respective monoamine in the sample was analysed. The 
linearity observed for serotonin, dopamine and norepi‑
nephrine was in the range of 0.993–0.996. The resulting 
data was expressed as µg/g of the weight of tissue.
Statistical analysis
GraphPad Prism 5.0. was used for statistical analysis. 
One‑way analysis of variance (ANOVA) followed by the 
Tukey test was used to compare the groups and to assess 
the associated statistical significance in the forced swim 
test and tail suspension test. Two‑way ANOVA followed 
by the Bonferroni post‑test was used to compare the 
groups and assess the associated statistical significance 
of brain monoamines. Representation of the data was as 
the mean ± SEM.
RESULTS 
Forced swim test 
The immobility period was reduced signifi cant‑
ly in groups that received treatment of ‘bupropion per 
se’ (10 mg/kg) and ‘bupropion + minocycline’ (5 mg/kg 
+ 25 mg/kg each), in comparison to the control group 
(Fig. 1; F5,30=3.4, P=0.015). 
Tail suspension test
The immobility time period was significantly de‑
creased in groups treated with ‘bupropion per se’ 
(10 mg/kg) and ‘bupropion + minocycline’ (5 mg/kg 
Fig. 1. Forced swim test. A significant diff erence is denoted by * ‑ p<0.05, ** ‑ p<0.01 *** ‑ p<0.001 — as compared against the vehicle‑treated group.
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+ 25 mg/kg) when compared against the control group 
(Fig. 2; F5,30=6.26, P=0.0004). 
Estimation of the norepinephrine level 
Hippocampus: A significant increase was observed 
in the levels of norepinephrine in ‘bupropion per se’ 
(10 mg/kg) and ‘bupropion + minocycline’ (5 mg/kg 
+ 25 mg/kg), as compared to the control group (Fig. 3A). 
The combination treated group when compared with ‘mi‑
nocycline per se’ (50 mg/kg) showed a significant rise in 
the levels of norepinephrine (Fig. 3A).
Cerebral cortex: Though the increase in norepineph‑
rine levels was observed in ‘minocycline per se’ (50 mg/kg), 
‘minocycline per se’ (25 mg/kg), and ‘bupropion + minocy‑
cline’ (5 mg/kg + 25 mg/kg), the difference was not statis‑
tically significant from the control group (Fig. 3A).
Whole brain: The combination treated group i.e. ‘bu‑
propion + minocycline’ (5 mg/kg + 25 mg/kg) showed 
a significant increase in the levels of norepinephrine 
from the control group (Fig. 3A). The combination treat‑
ed group also showed a significant increase in levels of 
norepinephrine from the ‘bupropion per se’ (5 mg/kg) 
treated group.
Estimation of dopamine level
Hippocampus: The treatment of drugs such as ‘bupro‑
pion per se’ (10 mg/kg) and the combination of ‘bupropion 
+ minocycline’ (5 mg/kg + 25 mg/kg) showed a significant 
increase in the levels of dopamine, in comparison to the 
control group (Fig. 3B). The combination treated group 
showed a significant increase in the levels of dopamine, in 
comparison to the ‘bupropion per se’ (10 mg/kg) treated 
group, ‘bupropion per se’ (5 mg/kg) treated group, ‘mino‑
cycline per se’ (50 mg/kg) treated group and the ‘minocy‑
cline per se’ (25 mg/kg) treated group, separately (Fig. 3B).
Cerebral cortex: The combination treated group i.e. 
‘bupropion + minocycline’ (5 mg/kg + 25 mg/kg) showed 
a significant increase in the levels of dopamine in cere‑
bral cortices in comparison to the minocycline per se’ 
(25 mg/kg) treated group (25 mg/kg) (Fig. 3B).
Whole brain: The levels of dopamine increased sig‑
nificantly in the ‘bupropion per se’ (10 mg/kg), ‘mino‑
cycline per se’ (50 mg/kg), and combination treated i.e. 
‘bupropion + minocycline’ (5 mg/kg + 25 mg/kg) treated 
groups in comparison to the control group. The combi‑
nation treated group showed a significant increase in the 
levels of dopamine, in comparison to the ‘bupropion per 
se’ (10 mg/kg) and ‘bupropion per se’ (5 mg/kg) treated 
group, ‘minocycline per se’ (50 mg/kg) treated group and 
‘minocycline per se’ (25 mg/kg) treated group, separately 
(Fig. 3B).
Estimation of serotonin level
Hippocampus: The combination treated group i.e. ‘bu‑
propion + minocycline’ (5 mg/kg + 25 mg/kg) showed a sig‑
nificant increase in the levels of serotonin in comparison 
to the control group (Fig. 3C). A significant increase in the 
levels of serotonin was also shown by the combination 
group in comparison to the ‘bupropion per se’ (10 mg/kg) 
treated group, ‘bupropion per se’ (5 mg/kg) treated group, 
‘minocycline per se’ (50 mg/kg) treated group and ‘minocy‑
cline per se’ (25 mg/kg) treated group, separately (Fig. 3C).
Fig. 2. Tail suspension test. A significant difference is denoted by * ‑ p>0.05, ** ‑ p<0.01 *** ‑ p<0.001 — as compared against the vehicle treated group.
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Fig. 3. Estimation of norepinephrine (A: Interaction – F10,90=3.25, P=0.0013; Treatment – F5,90=6.95, P<0.0001; Regions – F2,90=82.31, P<0.0001), dopamine (B: Interaction 
– F10,90=13.68, P<0.0001; Treatment – F5,90=68.28, P<0.0001; Regions – F2,90=311.88, P<0.0001) and serotonin (C: Interaction – F10,90=9.85, P<0.0001; Treatment – 
F5,90=53.42, P<0.0001; Regions – F2,90=143.9, P<0.0001) levels in hippocampi, cerebral cortices and whole brain using HPLC–FD. A significant difference is denoted by 
* – p<0.05,** – p<0.01,*** – p<0.001 – as compared against the control group; # – p<0.05, ## – p<0.01, ### – p<0.001– as compared against the bupropion (10 mg/kg) 
treated group; @ – p<0.05, @@ – p<0.01, 244 – p<0.001 – as compared against the minocycline (50 mg/kg) treated group, ^ – p<0.05, ^^ – p<0.01, ^^^ – p<0.001 – as 
compared against the bupropion (5 mg/kg) treated group; † – p< 0.05, †† – p< 0.01, ††† – p<0.001 – as compared against the minocycline (25 mg/kg) treated group.
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Cerebral cortex: A significant increase in dopamine 
levels was shown by the combination treated group i.e. 
‘bupropion + minocycline’ (5 mg/kg + 25 mg/kg) in ce‑
rebral cortices in comparison to the ‘minocycline per se’ 
(25 mg/kg) treated group (Fig. 3C).
Whole brain: A significant increase in the levels of se‑
rotonin was observed in the combination treated group 
i.e. ‘bupropion + minocycline’ (5 mg/kg + 25 mg/kg) in 
comparison to the control group. The combination treat‑
ed group also showed a significant increase in the lev‑
els of serotonin in comparison to the ‘bupropion per se’ 
(10 mg/kg) treated group, ‘bupropion per se’ (5 mg/kg) 
treated group, ‘minocycline per se’ (50 mg/kg) treated 
group and ‘minocycline per se’ (25 mg/kg) treated group, 
separately (Fig. 3C).
DISCUSSION
The antidepressant activity in the FST and TST is as‑
sociated with the immobility period arising out of the 
inescapable condition. These are commonly employed 
tests of antidepressant activity and are also used to in‑
fer “depression‑like” behaviour. In the TST, scores of 
immobility are taken while mice are suspended by their 
tails. Challenges related to thermoregulation are not 
encountered as water is not required in the TST (Cryan 
et al., 2005). Immobility in the FST or TST has been in‑
terpreted as an expression of behavioural despair or en‑
trapment (Lucki et al., 2001; Cryan et al., 2005), and is 
reversed by the acute administration of almost all avail‑
able antidepressants. This poses a problem for the mod‑
el, since antidepressants restore mood in depressed hu‑
mans only after many weeks of administration. Apart 
from this, the possibility of getting false positive results 
with drugs that enhance locomotor activity and a de‑
crease in the immobility time period (e.g. amphetamine) 
is higher in the FST. The differentiation of the acute and 
chronic antidepressant effect is also not possible in the 
FST. Interestingly, the observed significant difference 
in performance and drug effects in rodents from differ‑
ent strains indicates that the FST is sensitive to genet‑
ic variation (Porsolt et al., 1978; López‑Rubalcava et al., 
2000). The high reliability of the FST and TST has also 
contributed to their use and they are both considered 
useful for investigating differences between different 
strains reactivity to stress. The FST and TST have been 
used extensively for this purpose, but the selectivity of 
these tests for monoamine‑based mechanisms may limit 
their ability to detect novel mechanisms (Willner, 1990; 
Thiébot et al., 1992; Weiss and Kilts, 1995; Lucki, 1997). 
A recent study used the forced swim test and reported 
an interesting finding on the age‑dependent changes 
in serotonin transport levels in the lateral septum and 
dorsal raphe of rats (Ulloa et al., 2014). Prepubertal rats 
had less stress‑induced depressive responses, due to the 
higher availability of serotonin in the forced swim test, 
than pubertal (Ulloa et al., 2014). In animal studies, mi‑
nocycline reduced immobility by increasing climbing 
and enhanced the anti‑immobility effect of sub‑thresh‑
old doses of desipramine in the forced swim test (an an‑
tidepressant‑screening model) (Molina‑Hernández et al., 
2008). Deak et al. (2005) reported no change in climbing 
and swimming behaviour with minocycline. Amorim et 
al. (2017) showed changes in swimming behaviour with 
minocycline in diabetic mice. There are many preclin‑
ical studies reported by Reis et al. (2019) indicating an 
increase in locomotion with minocycline. Bupropion is 
also known to increase climbing behaviour in mice (Kale 
and Addepalli, 2014). Overall both drugs affect locomo‑
tion. There is a limitation in the present study due to the 
unavailability of swimming and climbing behaviour data 
to justify the immobility outcomes.
The antidepressant benefits of reducing the immobili‑
ty time period with bupropion (10 mg/kg) treatment were 
in line with available reports (Kale and Addepalli, 2014). 
The unavailability of pre‑clinical and clinical reports with 
the combination approach of minocycline and bupropion 
limits the discussion on benefits related to a reduction in 
immobility time period observed in the FST and TST, how‑
ever, the same was the advantage of the present study. 
Though there was a reduction in the immobility time pe‑
riod observed with minocycline (50 mg/kg) treatment, 
it was not statistically significant. The observed reduc‑
tion was in line with available reports (Henry et al., 2008; 
Zheng et al., 2015; Reis et al., 2019). 
The benefits of bupropion with an increase in norepi‑
nephrine, dopamine, and serotonin levels in the consid‑
ered brain regions were in line with the available reports 
(Piacentini et al., 2003; Kale and Addepalli, 2014). The 
increase in norepinephrine, dopamine, and serotonin 
levels with minocycline treatment were not statistically 
significant, however, the increment suggests benefits of 
minocycline treatment. Previous reports suggest a neu‑
roprotective role of minocycline in terms of an atten‑
uated decrease in norepinephrine, (Ahuja et al., 2008) 
dopamine, (Zhang et al., 2006a) and serotonin (Zhang et 
al., 2006b) levels. 
Bupropion metabolism mainly happens through 
CYP2B6. Other enzymes such as CYP1A2, 2A6, 2C9, 2D6, 
and 2E1 also play a role in bupropion metabolism (Jeffer‑
son et al., 2005). Reports related to minocycline metabo‑
lism are sparsely available (Nelis and De Leenheer, 1982). 
CYP450 might be playing an important role in minocy‑
cline metabolism. An in‑vitro study suggested a local in‑
hibition of cytochrome p450 (Husain et al., 2017). Reports 
related to minocycline affecting enzymes that metabolise 
brain monoamines are scarcely available. Du et al. (2001) 
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reported no alteration in monoamine oxidase activity. 
Study of minocycline effects on other related enzymes 
could be a separate avenue for further research. There is 
a strong need to study the metabolism of minocycline in 
preclinical and clinical trials. In addition, the metabolism 
related interaction between minocycline and bupropion 
may add an advantage. 
Overall, the bupropion plus minocycline treated 
group showed a better brain monoamine profile among 
the treated groups. There are no pre‑clinical or clinical 
reports available with the consideration of the same com‑
bination approach. Bupropion is associated with one of its 
severe side‑effects i.e. epileptic seizures with an increased 
dose. Other side‑effects include confusion, agitation, hal‑
lucinations, and coma (Hubbard, 2005; Kara et al., 2013). 
This combination approach may enhance the therapeutic 
activity, i.e. the antidepressant effect, with a reduction in 
the associated side‑effects, due to lowered doses, howev‑
er, the present study’s findings need further assessment 
in different preclinical and clinical conditions.
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